Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older, of any gender.
• People who are able to give written consent to participate.
• People whose general health and ability to carry out daily activities falls within an acceptable range, as rated by their doctor on a standard scale (ECOG score of 0 to 2).
• People with a confirmed diagnosis of Diffuse Large B-Cell Lymphoma (DLBCL), non-Hodgkin lymphoma, or High-Grade B-Cell Lymphoma (HGBCL), including certain subtypes with specific genetic changes (MYC, BCL2, and/or BCL6 rearrangements).
• People whose lymphoma has come back or stopped responding after a previous treatment called CAR-T cell therapy, meeting specific response criteria at defined timepoints after that treatment.
• People whose disease can be measured on imaging scans (PET-CT, CT, or MRI), as defined by standard medical guidelines.
• People who have previously been treated with a drug called Loncastuximab Tesirina, provided their disease was responding fully or partially when that treatment was stopped.
• Women who could become pregnant must have a negative pregnancy test within 7 days before the first dose.
• Women who could become pregnant must agree to use highly effective contraception from the time of consent until at least 9 months after the last dose; men with partners who could become pregnant must agree to use highly effective contraception until at least 6 months after the last dose.
• People whose kidneys, liver, lungs, and heart are functioning at an adequate level, as confirmed by specific blood and heart tests (confirm with trial site for exact values).
• People whose blood cell counts — including white blood cells, red blood cells, and platelets — meet minimum required levels (confirm with trial site for exact values).

Who may not be able to join:

• People with a known allergy or sensitivity to Loncastuximab Tesirina or any of its ingredients.
• Women who are pregnant or breastfeeding.
• People who have another active cancer, with some exceptions such as certain skin cancers, non-spreading prostate cancer, or early-stage cancers of the cervix or breast that the doctor considers unlikely to interfere with the study.
• People whose lymphoma has spread to the brain or spinal cord, including the membranes surrounding them.
• People with a tumour mass larger than 10 cm in diameter.
• People who have HIV, hepatitis B, or hepatitis C that requires antiviral treatment.
• People with a significant build-up of fluid in the body (such as in the abdomen or around the lungs) that needs to be drained or is causing breathing difficulties.
• People with serious ongoing health conditions, including uncontrolled high blood pressure, unstable chest pain, severe heart failure, a heart attack or heart procedure within the past 6 months, uncontrolled irregular heartbeat, poorly controlled diabetes, or severe chronic lung disease.
• People with an active autoimmune disease, particularly one affecting the nervous system.
• People with a history of severe skin reactions known as Stevens-Johnson syndrome or toxic epidermal necrolysis.
• People who have received chemotherapy, radiotherapy, or other cancer treatments within the 14 days before starting the study drug (unless approved by the study sponsor).
• People who are planning to receive a live vaccine after the first dose of the study drug.
• People who have taken another experimental drug or participated in another experimental therapy within 14 days before the first dose.
• People who have not yet recovered from side effects of previous chemotherapy or radiation to an acceptable level before screening.
• People with any other medical condition that the doctor running the trial considers would make participation unsafe or unsuitable.

Important: Always verify eligibility with the trial site directly before applying.